This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With this has come an increase in the size of the global clinicaltrials market, with an estimated worth of around $46.8 The lab has processed over 25,000 samples, participated in almost 60 clinicaltrials, and has partnered with over 25 different pharmaceutical companies. trillion, with oncologics accounting for $99.5
Experts discuss the therapeutic landscape, treatment gaps, regulatory considerations and clinicaltrial strategies. The webinar provides insights into a novel method that facilitates detailed geneticanalysis of breast cancer, marrying the depth of whole-genome studies with the precision of targeted analysis at the single-cell level.
Orphan drug development poses many challenges that are unique to rare diseases, including recruitment in small patient populations, variable progression with heterogenous clinical manifestations and limited understanding of disease progression and natural history.
For example, antisense oligonucleotide (ASO)-based therapies have gained traction, with 100 Phase I clinicaltrials initiated and around 25 percent of these advancing to Phase II or Phase III trials in recent years. The global NGS market is projected to grow from $13.0 billion in 2022 to $27.0 percent over this period.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content